

Robert B M LandewÃ©

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2671268/publications.pdf>

Version: 2024-02-01

433
papers

40,662
citations

4146
87
h-index

2895
190
g-index

436
all docs

436
docs citations

436
times ranked

20632
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to: â€˜Correspondence on â€˜Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC studyâ€™â€™ by Calvo-Aranda<i>et al</i>. Annals of the Rheumatic Diseases, 2023, 82, e35-e35.	0.9	6
2	Response to: â€™Correspondence on â€™Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC studyâ€™â€™ by Charles. Annals of the Rheumatic Diseases, 2023, 82, e109-e109.	0.9	2
3	Response to: â€˜Correspondence on â€˜Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC studyâ€™â€™ by De Santis<i>et al</i>. Annals of the Rheumatic Diseases, 2023, 82, e112-e112.	0.9	1
4	Response to: â€˜Correspondence on â€˜Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC studyâ€™â€™ by Kakkalmanos<i>et al</i>. Annals of the Rheumatic Diseases, 2023, 82, e135-e135.	0.9	0
5	Response to: Correspondence on â€˜No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related â€˜physician-reported spondylitisâ€™â€™ by Siebert and Marzo-Ortega. Annals of the Rheumatic Diseases, 2023, 82, e186-e186.	0.9	3
6	Instrument selection for the ASAS core outcome set for axial spondyloarthritis. Annals of the Rheumatic Diseases, 2023, 82, 763-772.	0.9	18
7	Response to: â€˜Should patients starting biologics be screened for COVID-19?â€™ by Cardenas-de la Garza<i>et al</i>. Annals of the Rheumatic Diseases, 2022, 81, e151-e151.	0.9	0
8	Response to: â€˜High dosage of Methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to Tocilizumabâ€™â€™ by Conticini<i>et al</i>. Annals of the Rheumatic Diseases, 2022, 81, e203-e203.	0.9	2
9	Response to: â€˜Reactive arthritis, a missing link: comment on the recent article from Sepriano<i>et al</i>â€™â€™ by Zeidler and Hudson. Annals of the Rheumatic Diseases, 2022, 81, e41-e41.	0.9	0
10	No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related â€˜physician-reported spondylitisâ€™â€™. Annals of the Rheumatic Diseases, 2022, 81, 466-468.	0.9	31
11	EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology. Annals of the Rheumatic Diseases, 2022, 81, 780-785.	0.9	12
12	Ultrasound-guided lymph node biopsy sampling to study the immunopathogenesis of rheumatoid arthritis: a well-tolerated valuable research tool. Arthritis Research and Therapy, 2022, 24, 36.	3.5	1
13	Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations. Annals of the Rheumatic Diseases, 2022, 81, 422-432.	0.9	75
14	EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. Annals of the Rheumatic Diseases, 2022, 81, 1628-1639.	0.9	89
15	Associations between syndesmophytes and facet joint ankylosis in radiographic axial spondyloarthritis patients on low-dose CT over 2 years. Rheumatology, 2022, 61, 4722-4730.	1.9	3
16	Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study. RMD Open, 2022, 8, e002138.	3.8	2
17	Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2022, 81, 937-943.	0.9	14
18	Response to: Correspondence on â€˜No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post hoc analyses of psoriatic arthritis-related â€˜physician-reported spondylitisâ€™â€™â€™ by Braun and LandewÄÄ. Annals of the Rheumatic Diseases, 2022, , annrheumdis-2022-222359.	0.9	2

#	ARTICLE	IF	CITATIONS
19	Does a short course of etanercept influence disease progression and radiographic changes in patients suspected of non-radiographic axial spondyloarthritis? Three -years follow- up of a placebo-controlled trial. Scandinavian Journal of Rheumatology, 2022, , 1-5.	1.1	0
20	MRI lesions of the spine in patients with axial spondyloarthritis: an update of lesion definitions and validation by the ASAS MRI working group. Annals of the Rheumatic Diseases, 2022, 81, 1243-1251.	0.9	22
21	Role of vertebral corner inflammation and fat deposition on MRI on syndesmophyte development detected on whole spine low-dose CT scan in radiographic axial spondyloarthritis. RMD Open, 2022, 8, e002250.	3.8	9
22	Development and validation of an alternative ankylosing spondylitis disease activity score when patient global assessment is unavailable. Rheumatology, 2021, 60, 638-648.	1.9	9
23	Use of multidimensional composite scores in rheumatology: parsimony versus subtlety. Annals of the Rheumatic Diseases, 2021, 80, 280-285.	0.9	17
24	Determinants of the patient global assessment of well-being in early axial spondyloarthritis: 5-year longitudinal data from the DESIR cohort. Rheumatology, 2021, 60, 316-321.	1.9	9
25	COVID-19 and how evidence of a new disease evolves. Annals of the Rheumatic Diseases, 2021, 80, 401-402.	0.9	3
26	Two different invitation approaches for consecutive rounds of a Delphi survey led to comparable final outcome. Journal of Clinical Epidemiology, 2021, 129, 31-39.	5.0	41
27	Assessment of radiographic progression in patients with rheumatoid arthritis treated with tofacitinib in long-term studies. Rheumatology, 2021, 60, 1708-1716.	1.9	4
28	Is Treatment in Patients With Suspected Nonradiographic Axial Spondyloarthritis Effective? Sixâ€Month Results of a Placeboâ€Controlled Trial. Arthritis and Rheumatology, 2021, 73, 806-815.	5.6	15
29	Disease activity is associated with spinal radiographic progression in axial spondyloarthritis independently of exposure to tumour necrosis factor inhibitors. Rheumatology, 2021, 60, 461-462.	1.9	10
30	Structural changes in the sacroiliac joint on MRI and relationship to ASDAS inactive disease in axial spondyloarthritis: a 2-year study comparing treatment with etanercept in EMBARK to a contemporary control cohort in DESIR. Arthritis Research and Therapy, 2021, 23, 43.	3.5	12
31	EULAR recommendations for the reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs). Annals of the Rheumatic Diseases, 2021, 80, 840-847.	0.9	31
32	Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study. RMD Open, 2021, 7, e001450.	3.8	64
33	Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Annals of the Rheumatic Diseases, 2021, 80, 727-738.	0.9	76
34	Radiographic sacroiliitis progression in axial spondyloarthritis: central reading of 5â€™year follow-up data from the Assessment of SpondyloArthritis international Society cohort.	1.9	7
35	A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis. Journal of Rheumatology, 2021, 48, 1259-1267.	2.0	8
36	Data-driven definitions for active and structural MRI lesions in the sacroiliac joint in spondyloarthritis and their predictive utility. Rheumatology, 2021, 60, 4778-4789.	1.9	44

#	ARTICLE	IF	CITATIONS
37	COVID-19-induced hyperinflammation, immunosuppression, recovery and survival: how causal inference may help draw robust conclusions. RMD Open, 2021, 7, e001638.	3.8	9
38	P133â€fFilgotinib in patients with RA with inadequate response to methotrexate: FINCH 1 52-week efficacy and patient reported outcomes data. Rheumatology, 2021, 60, .	1.9	0
39	The unsustainable bubble of disease-modifying antirheumatic drugs in rheumatology. Lancet Rheumatology, The, 2021, 3, e306-e312.	3.9	2
40	Antibody response to SARS-CoV-2 in patients receiving glucocorticoids with or without tocilizumab for COVID-19-associated hyperinflammation. Annals of the Rheumatic Diseases, 2021, 80, 1362-1363.	0.9	2
41	Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y). Annals of the Rheumatic Diseases, 2021, 80, 1022-1030.	0.9	18
42	Tumor Necrosis Factor Inhibitors Reduce Spinal Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: A Longitudinal Analysis From the Alberta Prospective Cohort. Arthritis and Rheumatology, 2021, 73, 1211-1219.	5.6	25
43	Definition of Treatment Targets in Rheumatoid Arthritis: Is It Time for Reappraisal?. Journal of Rheumatology, 2021, 48, 1763-1766.	2.0	8
44	Reply. Arthritis and Rheumatology, 2021, 73, 2352-2353.	5.6	0
45	Response to: â€Correspondence on â€Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19- associated cytokine storm syndrome: results of the CHIC studyâ€™â€™ by Klopfenstein et al. Annals of the Rheumatic Diseases, 2021, , annrhumdis-2021-220787.	0.9	0
46	Sick leave in early axial spondyloarthritis: the role of clinical and socioeconomic factors. Five-year data from the DESIR cohort. RMD Open, 2021, 7, e001685.	3.8	6
47	Biological DMARDs and disease modification in axial spondyloarthritis: a review through the lens of causal inference. RMD Open, 2021, 7, e001654.	3.8	16
48	Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study. RMD Open, 2021, 7, e001600.	3.8	18
49	Progression from subclinical inflammation to overt SpA in first degree relatives of SpA patients is associated with HLAâ€B27: the Preâ€SpA cohort. Arthritis Care and Research, 2021, , .	3.4	9
50	Domains to Be Considered for the Core Outcome Set of Axial Spondyloarthritis: Results From a 3-round Delphi Survey. Journal of Rheumatology, 2021, 48, 1810-1814.	2.0	3
51	Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Annals of the Rheumatic Diseases, 2021, 80, 848-858.	0.9	123
52	Hemocytometric characteristics of COVID-19 patients with and without cytokine storm syndrome on the sysmex XN-10 hematology analyzer. Clinical Chemistry and Laboratory Medicine, 2021, 59, 783-793.	2.3	26
53	Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial. Rheumatology, 2021, , .	1.9	10
54	Identification of clinical phenotypes of peripheral involvement in patients with spondyloarthritis, including psoriatic arthritis: a cluster analysis in the worldwide ASAS-PerSpA study. RMD Open, 2021, 7, e001728.	3.8	5

#	ARTICLE	IF	CITATIONS
55	Three-month and six-month outcomes of patients with COVID-19 associated hyperinflammation treated with short-term immunosuppressive therapy: follow-up of the CHIC study. RMD Open, 2021, 7, e001906.	3.8	4
56	Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology. RMD Open, 2021, 7, e001818.	3.8	4
57	The Development and Evaluation of Personalized Training in Shared Decision-making Skills for Rheumatologists. Journal of Rheumatology, 2020, 47, 290-297.	2.0	3
58	Association of 17 Definitions of Remission with Functional Status in a Large Clinical Practice Cohort of Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2020, 47, 20-27.	2.0	3
59	Response to: "Catching the falling star: points to consider when using propensity scores" by Ouyang et al. Annals of the Rheumatic Diseases, 2020, 79, e27-e27.	0.9	1
60	Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5. Rheumatology, 2020, 59, 1325-1334.	1.9	40
61	Adherence to Treat-to-target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort. Journal of Rheumatology, 2020, 47, 809-819.	2.0	16
62	2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Annals of the Rheumatic Diseases, 2020, 79, 39-52.	0.9	506
63	Validation of the self-administered comorbidity questionnaire adjusted for spondyloarthritis: results from the ASAS-COMOSPA study. Rheumatology, 2020, 59, 1632-1639.	1.9	3
64	Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Annals of the Rheumatic Diseases, 2020, 79, 176-185.	0.9	76
65	Infliximab treatment reduces depressive symptoms in patients with ankylosing spondylitis: an ancillary study to a randomized controlled trial (ASSERT). Arthritis Research and Therapy, 2020, 22, 225.	3.5	8
66	Which imaging outcomes for axSpA are most sensitive to change? A 5-year analysis of The DESIR Cohort. Arthritis Care and Research, 2020, , .	3.4	5
67	Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study. Annals of the Rheumatic Diseases, 2020, 79, 1143-1151.	0.9	187
68	Response to "Neither earlier nor late tocilizumab improved outcomes in the intensive care unit patients with COVID-19 in a retrospective cohort study" by Moiseev et al. Annals of the Rheumatic Diseases, 2020, , annrheumdis-2020-219295.	0.9	1
69	Comparative construct validity of three presenteeism instruments in workers with musculoskeletal complaints: a prospective cohort study. RMD Open, 2020, 6, e001281.	3.8	4
70	Which disease activity outcome measure discriminates best in axial spondyloarthritis? A systematic literature review and meta-analysis. Rheumatology, 2020, 59, 3990-3992.	1.9	3
71	P62 Assessing the effect of increased body mass on response to DMARD treatment in rheumatoid arthritis: results from the METEOR database. Rheumatology, 2020, 59, .	1.9	0
72	Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction. Annals of the Rheumatic Diseases, 2020, 79, 920-928.	0.9	53

#	ARTICLE	IF	CITATIONS
73	Central reader evaluation of MRI scans of the sacroiliac joints from the ASAS classification cohort: discrepancies with local readers and impact on the performance of the ASAS criteria. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 935-942.	0.9	14
74	Do Illness Perceptions and Coping Strategies Change Over Time in Patients Recently Diagnosed With Axial Spondyloarthritis?. <i>Journal of Rheumatology</i> , 2020, 47, 1752-1759.	2.0	9
75	EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 700.1-712.	0.9	609
76	Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE. <i>Rheumatology and Therapy</i> , 2020, 7, 581-599.	2.3	13
77	EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 851-858.	0.9	204
78	Do Smoking and Socioeconomic Factors Influence Imaging Outcomes in Axial Spondyloarthritis? Five-Year Data From the DESIR Cohort. <i>Arthritis and Rheumatology</i> , 2020, 72, 1855-1862.	5.6	19
79	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 760-770.	0.9	205
80	Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM). <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 453-459.	0.9	43
81	Spinal radiographic progression in axial spondyloarthritis and the impact of classification as nonradiographic versus radiographic disease: Data from the Swiss Clinical Quality Management cohort. <i>PLoS ONE</i> , 2020, 15, e0230268.	2.5	17
82	Integrated longitudinal analysis does not compromise precision and reduces bias in the study of imaging outcomes: A comparative 5-year analysis in the DESIR cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1394-1399.	3.4	5
83	Outcomes and Findings of the International Rheumatoid Arthritis (RA) BIODAM Cohort for Validation of Soluble Biomarkers in RA. <i>Journal of Rheumatology</i> , 2020, 47, 796-808.	2.0	3
84	Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 744-759.	0.9	167
85	The earlier, the better or the worse? Towards accurate management of patients with arthralgia at risk for RA. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 312-315.	0.9	12
86	The role of biochemical markers of joint tissue remodelling to predict progression and treatment efficacy in inflammatory rheumatic diseases. <i>Rheumatology</i> , 2020, 59, 1207-1217.	1.9	4
87	What is axial spondyloarthritis? A latent class and transition analysis in the SPACE and DESIR cohorts. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 324-331.	0.9	41
88	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 685-699.	0.9	1,860
89	Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 193-201.	0.9	59
90	Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome. <i>European Journal of Case Reports in Internal Medicine</i> , 2020, 7, 1.	0.4	17

#	ARTICLE	IF	CITATIONS
91	Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis. Rheumatology, 2019, 58, 388-400.	1.9	93
92	Response to: 'Dual target strategy: a proposal to mitigate the risk of overtreatment and enhance patient satisfaction in rheumatoid arthritis' by Ferreira et al. Annals of the Rheumatic Diseases, 2019, 78, e110-e110.	0.9	6
93	Response to: 'Early identification of rheumatoid arthritis; the risk of overtreatment in perspective' by LandewäÄ. Annals of the Rheumatic Diseases, 2019, 78, e108-e108.	0.9	3
94	Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study. RMD Open, 2019, 5, e000917.	3.8	30
95	Inhibition of spinal bone formation in AS: 10 years after comparing adalimumab to OASIS. Arthritis Research and Therapy, 2019, 21, 225.	3.5	6
96	Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes. Cell Reports, 2019, 28, 2455-2470.e5.	6.4	241
97	MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group. Annals of the Rheumatic Diseases, 2019, 78, 1550-1558.	0.9	171
98	Three handy tips and a practical guide to improve your propensity score models. RMD Open, 2019, 5, e000953.	3.8	33
99	Predictors of biologic-free disease control in patients with rheumatoid arthritis after stopping tumor necrosis factor inhibitor treatment. BMC Rheumatology, 2019, 3, 3.	1.6	4
100	Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study. Annals of the Rheumatic Diseases, 2019, 78, 1033-1040.	0.9	39
101	A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis. Arthritis and Rheumatology, 2019, 71, 1101-1111.	5.6	71
102	Percentage of progressors in imaging: can we ignore regressors?. RMD Open, 2019, 5, e000848.	3.8	12
103	Individual-level and country-level socioeconomic determinants of disease outcomes in SpA: multinational, cross-sectional study (ASAS-COMOSPA). Annals of the Rheumatic Diseases, 2019, 78, 486-493.	0.9	24
104	Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients. Annals of the Rheumatic Diseases, 2019, 78, 761-772.	0.9	219
105	Is a positive family history of spondyloarthritis relevant for diagnosing axial spondyloarthritis once HLA-B27 status is known?. Rheumatology, 2019, 58, 1649-1654.	1.9	23
106	Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time. RMD Open, 2019, 5, e000836.	3.8	5
107	Systematic review of rheumatoid arthritis clinical studies: Suboptimal statistical analysis of radiological data. Seminars in Arthritis and Rheumatism, 2019, 49, 218-221.	3.4	1
108	FRI0397...EFFICACY AND SAFETY OUTCOMES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL: RESULTS FROM THE 48-WEEK RUN-IN PART OF C-OPTIMISE. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
109	OP0037â€...ASSOCIATION BETWEEN BONE MARROW EDEMA AND STRUCTURAL PROGRESSION IN THE SAME QUADRANT IN AXIAL SPONDYLOARTHRITIS â€“ 5-YEAR DATA FROM THE DESIR COHORT. , 2019, , .		0
110	SAT0349â€...HIGHER DISEASE ACTIVITY IS ASSOCIATED WITH MORE SPINAL RADIOGRAPHIC PROGRESSION IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS. , 2019, , .		0
111	OP0034â€...DO SMOKING AND SOCIO-ECONOMIC FACTORS INDEPENDENTLY INFLUENCE IMAGING OUTCOMES IN AXIAL SPONDYLOARTHRITIS? FIVE-YEAR DATA FROM THE DESIR COHORT. , 2019, , .		0
112	AB0711â€...IXEKIZUMAB IMPROVES SIGNS AND SYMPTOMS AND SPINAL INFLAMMATION OF ANKYLOSING SPONDYLITIS/RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THROUGH ONE YEAR OF TREATMENT IN BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUG-NAËVE PATIENTS. , 2019, , .		0
113	FRI0410â€...TNF INHIBITORS REDUCE SPINAL RADIOGRAPHIC PROGRESSION IN AXIAL SPONDYLOARTHRITIS (PARTIALLY) BY DECREASING DISEASE ACTIVITY. , 2019, , .		0
114	OP0033â€...WHAT IS AXIAL SPONDYLOARTHRITIS? A LATENT CLASS AND TRANSITION ANALYSIS IN THE SPACE AND DESIR COHORTS. , 2019, , .		0
115	THU0358â€...DEVELOPMENT OF A SET OF ASAS QUALITY STANDARDS FOR ADULTS WITH AXIAL SPONDYLOARTHRITIS. , 2019, , .		0
116	THU0360â€...INCREASING IMPACT ON STRUCTURAL DAMAGE WITH INCREASING CUMULATIVE INFLAMMATION AT THE SI-JOINT QUADRANT LEVEL IN AXIAL SPONDYLOARTHRITIS â€“ 5-YEAR DATA FROM THE DESIR COHORT. , 2019, , .		0
117	SAT0309â€...CLINICAL, IMAGING AND BIOLOGIC FEATURES OF SPONDYLOARTHRITIS IN AN AT-RISK POPULATION: DATA FROM THE PRE-SPA COHORT. , 2019, , .		0
118	THU0363â€...DO ILLNESS PERCEPTIONS AND COPING CHANGE OVER TIME IN PATIENTS RECENTLY DIAGNOSED WITH AXIAL SPONDYLOARTHRITIS? A 2-YEAR FOLLOW-UP STUDY IN THE SPACE COHORT. , 2019, , .		0
119	FRI0408â€...EARLIER TREATMENT OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH CERTOLIZUMAB PEGOL RESULTS IN IMPROVED CLINICAL OUTCOMES. , 2019, , .		1
120	LB0001â€...EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: FINCH1 PRIMARY OUTCOME RESULTS. , 2019, , .		15
121	LB0003â€...EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS NAËVE TO METHOTREXATE THERAPY: FINCH3 PRIMARY OUTCOME RESULTS. , 2019, , .		5
122	LB0006â€...SUBCUTANEOUS SECUKINUMAB 300MG AND 150MG PROVIDES SUSTAINED INHIBITION OF RADIOGRAPHIC PROGRESSION IN PSORIATIC ARTHRITIS OVER 2 YEARS: RESULTS FROM THE PHASE 3 FUTURE-5 TRIAL. , 2019, , .		1
123	Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open, 2019, 5, e001041.	3.8	104
124	Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations. RMD Open, 2019, 5, e001035.	3.8	113
125	Routine Assessment of Patient Index Data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practice. RMD Open, 2019, 5, e001050.	3.8	14
126	Do we need new trial designs in spondyloarthritis?. Seminars in Arthritis and Rheumatism, 2019, 49, S8-S10.	3.4	2

#	ARTICLE	IF	CITATIONS
127	Is active sacroiliitis on MRI associated with radiographic damage in axial spondyloarthritis? Real-life data from the ASAS and DESIR cohorts. <i>Rheumatology</i> , 2019, 58, 798-802.	1.9	11
128	Response to: "Metering the METEOR in methotrexate failure: is propensity score a falling star?" by Ahmed et al. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e132-e132.	0.9	0
129	Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity. <i>Rheumatology</i> , 2019, 58, 1025-1033.	1.9	13
130	How to treat patients with rheumatoid arthritis when methotrexate has failed? The use of a multiple propensity score to adjust for confounding by indication in observational studies. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 25-30.	0.9	14
131	Alternative diagnoses in patients with chronic back pain not diagnosed with axial spondyloarthritis: data from the SPACE cohort. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2017-212175.	0.9	3
132	Magnetic Resonance Imaging of the Sacroiliac Joints Indicating Sacroiliitis According to the Assessment of SpondyloArthritis international Society Definition in Healthy Individuals, Runners, and Women With Postpartum Back Pain. <i>Arthritis and Rheumatology</i> , 2018, 70, 1042-1048.	5.6	175
133	Are MRI-detected erosions specific for RA? A large explorative cross-sectional study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2017-212252.	0.9	20
134	"Big Data" in Rheumatology. <i>Rheumatic Disease Clinics of North America</i> , 2018, 44, 307-315.	1.9	12
135	The Impact of Illness Perceptions and Coping on the Association Between Back Pain and Health Outcomes in Patients Suspected of Having Axial Spondyloarthritis: Data From the SpondyloArthritis Caught Early Cohort. <i>Arthritis Care and Research</i> , 2018, 70, 1829-1839.	3.4	21
136	Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1539-1540.	0.9	159
137	Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort. <i>Journal of Rheumatology</i> , 2018, 45, 506-512.	2.0	31
138	Evaluation of the change in structural radiographic sacroiliac joint damage after 2 years of etanercept therapy (EMBARK trial) in comparison to a contemporary control cohort (DESIR cohort) in recent onset axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 221-227.	0.9	40
139	Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 699-705.	0.9	98
140	Imaging of the sacroiliac joints is important for diagnosing early axial spondyloarthritis but not all-decisive. <i>Rheumatology</i> , 2018, 57, 1173-1179.	1.9	12
141	Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2017-212687.	0.9	193
142	Impact of replacing radiographic sacroiliitis by magnetic resonance imaging structural lesions on the classification of patients with axial spondyloarthritis. <i>Rheumatology</i> , 2018, 57, 1186-1193.	1.9	11
143	In Early Axial Spondyloarthritis, Increasing Disease Activity Is Associated with Worsening of Health-related Quality of Life over Time. <i>Journal of Rheumatology</i> , 2018, 45, 779-784.	2.0	10
144	The influence of discrepant imaging judgements on the classification of axial spondyloarthritis is limited: a replication in the SpondyloArthritis Caught Early (SPACE) cohort. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e1-e1.	0.9	6

#	ARTICLE	IF	CITATIONS
145	In patients with axial spondyloarthritis, inflammation on MRI of the spine is longitudinally related to disease activity only in men: 2 years of the axial spondyloarthritis DESIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 470-472.	0.9	8
146	How are enthesitis, dactylitis and nail involvement measured and reported in recent clinical trials of psoriatic arthritis? A systematic literature review. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 782-783.	0.9	18
147	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 3-17.	0.9	484
148	Social Role Participation and Satisfaction With Life: A Study Among Patients With Ankylosing Spondylitis and Population Controls. <i>Arthritis Care and Research</i> , 2018, 70, 600-607.	3.4	15
149	Should radiographic progression still be used as outcome in RA?. <i>Clinical Immunology</i> , 2018, 186, 79-81.	3.2	16
150	Impact of Stopping Tumor Necrosis Factor Inhibitors on Rheumatoid Arthritis Patientsâ€™ Burden of Disease. <i>Arthritis Care and Research</i> , 2018, 70, 516-524.	3.4	10
151	An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 124-127.	0.9	51
152	TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 63-69.	0.9	220
153	Inequity in biological DMARD prescription for spondyloarthritis across the globe: results from the ASAS-COMOSPA study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 405-411.	0.9	34
154	Prevalence of Comorbidities and Risk Factors for Comorbidities in Patients with Spondyloarthritis in Latin America: A Comparative Study with the General Population and Data from the ASAS-COMOSPA Study. <i>Journal of Rheumatology</i> , 2018, 45, 206-212.	2.0	31
155	Depressive mood and low social support are not associated with arthritis development in patients with seropositive arthralgia, although they predict increased musculoskeletal symptoms. <i>RMD Open</i> , 2018, 4, e000653.	3.8	8
156	Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies. <i>RMD Open</i> , 2018, 4, e000749.	3.8	30
157	Uncovering the heterogeneity of disease impact in axial spondyloarthritis: bivariate trajectories of disease activity and quality of life. <i>RMD Open</i> , 2018, 4, e000755.	3.8	15
158	Response to: â€˜The GRAPPA-OMERACT initiative to standardise outcomes in Psoriatic Arthritis clinical trials and longitudinal observational studiesâ€™ by Tillett <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e24-e24.	0.9	1
159	Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study. <i>RMD Open</i> , 2018, 4, e000766.	3.8	16
160	Validation and reliability of translation of the ASAS Health Index in a Colombian Spanish-speaking population with spondyloarthritis. <i>Clinical Rheumatology</i> , 2018, 37, 3063-3068.	2.2	9
161	Are gender-specific approaches needed in diagnosing early axial spondyloarthritis? Data from the SPondyloArthritis Caught Early cohort. <i>Arthritis Research and Therapy</i> , 2018, 20, 218.	3.5	41
162	Is radiographic progression in radiographic axial spondyloarthritis related to matrix metalloproteinase degradation of extracellular matrix?. <i>RMD Open</i> , 2018, 4, e000648.	3.8	7

#	ARTICLE	IF	CITATIONS
163	A single determination of C-reactive protein does not suffice to declare a patient with a diagnosis of axial spondyloarthritis â€˜CRP-negativeâ€™™. Arthritis Research and Therapy, 2018, 20, 209.	3.5	23
164	Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet, The, 2018, 392, 2441-2451.	13.7	251
165	Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet, The, 2018, 392, 2378-2387.	13.7	198
166	Are globals for health, well-being and quality of life interchangeable? A mixed methods study in ankylosing spondylitis patients and controls. Rheumatology, 2018, 57, 1555-1562.	1.9	3
167	Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. Lancet, The, 2018, 392, 134-144.	13.7	81
168	Frequency of Impaired Spinal Mobility in Patients with Chronic Back Pain Compared to Patients with Early Axial Spondyloarthritis. Journal of Rheumatology, 2018, 45, 1643-1650.	2.0	11
169	Overdiagnosis and overtreatment in rheumatology: a little caution is in order. Annals of the Rheumatic Diseases, 2018, 77, 1394-1396.	0.9	62
170	Do ethnicity, degree of family relationship, and the spondyloarthritis subtype in affected relatives influence the association between a positive family history for spondyloarthritis and HLA-B27 carriership? Results from the worldwide ASAS cohort. Arthritis Research and Therapy, 2018, 20, 166.	3.5	16
171	Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry. Annals of the Rheumatic Diseases, 2018, 77, 1413-1420.	0.9	69
172	An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity. Arthritis and Rheumatology, 2018, 70, 1557-1564.	5.6	17
173	Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial. Arthritis Research and Therapy, 2018, 20, 174.	3.5	18
174	Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment. PLoS ONE, 2018, 13, e0192425.	2.5	17
175	Work participation in spondyloarthritis across countries: analysis from the ASAS-COMOSPA study. Annals of the Rheumatic Diseases, 2018, 77, 1303-1310.	0.9	18
176	Sex-associated Treatment Differences and Their Outcomes in Rheumatoid Arthritis: Results from the METEOR Register. Journal of Rheumatology, 2018, 45, 1361-1366.	2.0	16
177	Short-term changes on MRI predict long-term changes on radiography in rheumatoid arthritis: an analysis by an OMERACT Task Force of pooled data from four randomised controlled trials. Annals of the Rheumatic Diseases, 2017, 76, 992-997.	0.9	17
178	2016 update of the EULAR recommendations for the management of early arthritis. Annals of the Rheumatic Diseases, 2017, 76, 948-959.	0.9	393
179	Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 1113-1136.	0.9	195
180	Non-pharmacological and pharmacological interventions in patients with early arthritis: a systematic literature review informing the 2016 update of EULAR recommendations for the management of early arthritis. RMD Open, 2017, 3, e000404.	3.8	43

#	ARTICLE	IF	CITATIONS
181	Diagnosis, prognosis and classification of early arthritis: results of a systematic review informing the 2016 update of the EULAR recommendations for the management of early arthritis. RMD Open, 2017, 3, e000406.	3.8	41
182	Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 414-417.	0.9	94
183	2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Annals of the Rheumatic Diseases, 2017, 76, 978-991.	0.9	1,220
184	Performance of the ASAS classification criteria for axial and peripheral spondyloarthritis: a systematic literature review and meta-analysis. Annals of the Rheumatic Diseases, 2017, 76, 886-890.	0.9	51
185	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the Rheumatic Diseases, 2017, 76, 960-977.	0.9	3,366
186	Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. RMD Open, 2017, 3, e000396.	3.8	99
187	Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. RMD Open, 2017, 3, e000397.	3.8	69
188	What causes a small increase in radiographic progression in rheumatoid arthritis patients tapering TNF inhibitors?. RMD Open, 2017, 3, e000327.	3.8	6
189	Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA. Rheumatology, 2017, 56, 1498-1509.	1.9	78
190	Reply. Arthritis and Rheumatology, 2017, 69, 1124-1125.	5.6	0
191	Response to: "2016 update of the EULAR recommendations for the management of rheumatoid arthritis: no utopia for patients in low/middle-income countries?" by Misra et al. Annals of the Rheumatic Diseases, 2017, 76, e48-e48.	0.9	4
192	Response to: "The time has come to revisit alternative interpretations of data underlying the EULAR management recommendations for rheumatoid arthritis" by PiriÄ et al. Annals of the Rheumatic Diseases, 2017, 76, e50-e50.	0.9	0
193	Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis. RMD Open, 2017, 3, e000430.	3.8	28
194	Appropriate use of the EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, e15-e15.	0.9	0
195	Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 1102-1107.	0.9	131
196	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 1101-1136.	0.9	277
197	Evaluating quality of care in rheumatoid arthritis: the patient perspective. RMD Open, 2017, 3, e000411.	3.8	5
198	Why CAPS criteria are not diagnostic criteria?. Annals of the Rheumatic Diseases, 2017, 76, e7-e7.	0.9	6

#	ARTICLE	IF	CITATIONS
199	Rheumatoid arthritis patients with continued low disease activity have similar outcomes over 10 years, regardless of initial therapy. <i>Rheumatology</i> , 2017, 56, 1721-1728.	1.9	4
200	Sacroiliac radiographic progression in recent onset axial spondyloarthritis: the 5-year data of the DESIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1823-1828.	0.9	130
201	The performance of different classification criteria sets for spondyloarthritis in the worldwide ASAS-COMOSPA study. <i>Arthritis Research and Therapy</i> , 2017, 19, 96.	3.5	16
202	Is the current ASAS expert definition of a positive family history useful in identifying axial spondyloarthritis? Results from the SPACE and DESIR cohorts. <i>Arthritis Research and Therapy</i> , 2017, 19, 118.	3.5	16
203	The yield of a positive MRI of the spine as imaging criterion in the ASAS classification criteria for axial spondyloarthritis: results from the SPACE and DESIR cohorts. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1731-1736.	0.9	42
204	Is the Site of Back Pain Related to the Location of Magnetic Resonance Imaging Lesions in Patients With Chronic Back Pain? Results From the Spondyloarthritis Caught Early Cohort. <i>Arthritis Care and Research</i> , 2017, 69, 717-723.	3.4	20
205	Lessons to be learned from serum biomarkers in psoriasis and IBD – the potential role in SpA. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 333-344.	3.0	16
206	Serum inflammatory biomarkers fail to identify early axial spondyloarthritis: results from the SpondyloArthritis Caught Early (SPACE) cohort. <i>RMD Open</i> , 2017, 3, e000319.	3.8	40
207	Is there a relationship between spondyloarthritis and periodontitis? A case–control study. <i>RMD Open</i> , 2017, 3, e000547.	3.8	5
208	Validation of the EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. <i>Rheumatology</i> , 2017, 56, 2123-2128.	1.9	45
209	Disease activity decrease is associated with improvement in work productivity over 1 year in early axial spondyloarthritis (SPondyloArthritis Caught Early cohort). <i>Rheumatology</i> , 2017, 56, 2222-2228.	1.9	18
210	Further Treatment Intensification in Undifferentiated and Rheumatoid Arthritis Patients Already in Low Disease Activity has Limited Benefit towards Physical Functioning. <i>Arthritis Research and Therapy</i> , 2017, 19, 220.	3.5	4
211	Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 258.	3.5	3
212	Factors associated with the decision of the rheumatologist to order sacroiliac joints magnetic resonance imaging (SI-MRI) or HLA-B27 testing in the diagnostic work-up of patients with spondyloarthritis in clinical practice. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 122-128.	0.8	2
213	Gender-attributable differences in outcome of ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study. <i>Rheumatology</i> , 2016, 55, kev340.	1.9	66
214	THU0069 – Influence of The Difference between Patient and Physician Global Assessment on Disease Activity Status in High and Lower Income Countries: Data from The Meteor Database. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 203.2-204.	0.9	0
215	Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials. <i>Arthritis Research and Therapy</i> , 2016, 18, 212.	3.5	27
216	O49 – Synovial Lymphocytic Aggregates Associate with Highly Active RA and Predict Erosive Disease Progression at 12 Months: Results from the Pathobiology of Early Arthritis Cohort. <i>Rheumatology</i> , 2016, . .	1.9	0

#	ARTICLE	IF	CITATIONS
217	New concepts of clinical trials in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2016, 28, 316-322.	4.3	5
218	Injection intra-articulaire d'Ä©tanercept dans le traitement local des rhumatismes inflammatoiresÄ: Ä©tude pilote contrÄ©e avec Ä©tude de mÄ©canisme. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2016, 83, 274-280.	0.0	0
219	Clinical and Imaging Signs of Spondyloarthritis in First-Degree Relatives of HLA-B27-Positive Ankylosing Spondylitis Patients: The Pre-Spondyloarthritis (Pre-SpA) Cohort Study. <i>Arthritis and Rheumatology</i> , 2016, 68, 2444-2455.	5.6	18
220	Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open-Label Randomized Controlled Trial. <i>Arthritis and Rheumatology</i> , 2016, 68, 1810-1817.	5.6	70
221	When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS). <i>RMD Open</i> , 2016, 2, e000221.	3.8	38
222	The Minimum Clinically Important Improvement and Patient-acceptable Symptom State in the BASDAI and BASFI for Patients with Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2016, 43, 1680-1686.	2.0	42
223	Fluctuations in patient reported disease activity, pain and global being in patients with ankylosing spondylitis. <i>Rheumatology</i> , 2016, 55, 2014-2022.	1.9	15
224	Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis. <i>Arthritis Research and Therapy</i> , 2016, 18, 196.	3.5	192
225	Does body mass index (BMI) influence the Ankylosing Spondylitis Disease Activity Score in axial spondyloarthritis?. <i>RMD Open</i> , 2016, 2, e000283.	3.8	26
226	Social Role Participation Questionnaire for patients with ankylosing spondylitis: translation into Dutch, reliability and construct validity. <i>RMD Open</i> , 2016, 2, e000177.	3.8	7
227	Are conventional radiographs still of value?. <i>Current Opinion in Rheumatology</i> , 2016, 28, 310-315.	4.3	3
228	Linear extrapolation of missing radiographic change scores in clinical trials does not spuriously overestimate group radiographic changes in rheumatoid arthritis. <i>Rheumatology</i> , 2016, 55, 1295-1300.	1.9	8
229	Erosions in the foot at baseline are predictive of orthopaedic shoe use after 10-years of treat to target therapy in patients with recent onset rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2016, 35, 2101-2107.	2.2	2
230	DAS steered therapy in clinical practice; cross-sectional results from the METEOR database. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 33.	1.9	2
231	Resource utilisation and direct costs in patients with recently diagnosed fibromyalgia who are offered one of three different interventions in a randomised pragmatic trial. <i>Clinical Rheumatology</i> , 2016, 35, 1307-1315.	2.2	7
232	Social Role Participation in Patients With Ankylosing Spondylitis: A Cross-Sectional Comparison With Population Controls. <i>Arthritis Care and Research</i> , 2016, 68, 1899-1905.	3.4	15
233	Digital ulcers predict a worse disease course in patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 681-686.	0.9	111
234	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 3-15.	0.9	1,114

#	ARTICLE	IF	CITATIONS
235	Analysis and performance of various classification criteria sets in a Colombian cohort of patients with spondyloarthritis. <i>Clinical Rheumatology</i> , 2016, 35, 1759-1767.	2.2	22
236	Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1958-1963.	0.9	383
237	A psychometric analysis of outcome measures in peripheral spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1302-1307.	0.9	22
238	Less educated and older patients have reduced access to biologic DMARDs even in a country with highly developed social welfare (Norway): results from Norwegian cohort study NOR-DMARD. <i>Rheumatology</i> , 2016, 55, 1217-1224.	1.9	31
239	Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1034-1042.	0.9	53
240	Nonsteroidal Antiinflammatory Drugs for Axial Spondyloarthritis: A Cochrane Review. <i>Journal of Rheumatology</i> , 2016, 43, 607-617.	2.0	32
241	Preliminary definitions of "flare"™ in axial spondyloarthritis, based on pain, BASDAI and ASDAS-CRP: an ASAS initiative. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 991-996.	0.9	48
242	Five-year follow-up of radiographic sacroiliitis: progression as well as improvement?. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1262-1263.	0.9	24
243	Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 490-498.	0.9	98
244	MRI vertebral corner inflammation followed by fat deposition is the strongest contributor to the development of new bone at the same vertebral corner: a multilevel longitudinal analysis in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1486-1493.	0.9	103
245	Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1016-1023.	0.9	188
246	Disease activity is longitudinally related to sacroiliac inflammation on MRI in male patients with axial spondyloarthritis: 2-years of the DESIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 874-878.	0.9	49
247	Prevalence of degenerative changes of the spine on magnetic resonance images and radiographs in patients aged 16-45 years with chronic back pain of short duration in the Spondyloarthritis Caught Early (SPACE) cohort. <i>Rheumatology</i> , 2016, 55, 56-65.	1.9	45
248	Patients with chronic back pain of short duration from the SPACE cohort: which MRI structural lesions in the sacroiliac joints and inflammatory and structural lesions in the spine are most specific for axial spondyloarthritis?. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1308-1314.	0.9	84
249	Association of the different types of radiographic damage with physical function in patients with rheumatoid arthritis: analysis of the RAPID trials. <i>RMD Open</i> , 2016, 2, e000219.	3.8	8
250	Do extra-articular manifestations influence outcome in ankylosing spondylitis? 12-year results from OASIS. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 214-21.	0.8	10
251	Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysis. <i>RMD Open</i> , 2015, 1, e000153.	3.8	85
252	Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors?. <i>RMD Open</i> , 2015, 1, e000155-e000155.	3.8	34

#	ARTICLE	IF	CITATIONS
253	Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis. Arthritis Research and Therapy, 2015, 17, 133.	3.5	17
254	Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients. Arthritis Research and Therapy, 2015, 17, 245.	3.5	22
255	Assessment of Global Disease Activity in Rheumatoid Arthritis by Patients and Physicians. Journal of Clinical Rheumatology, 2015, 21, 349-354.	0.9	7
256	Cardiovascular Morbidity and Mortality Among Working Individuals With Rheumatic Disease. Journal of Clinical Rheumatology, 2015, 21, 359-363.	0.9	2
257	Hierarchy of Impairment of Spinal Mobility Measures in Ankylosing Spondylitis: Twelve-Year Data. Arthritis Care and Research, 2015, 67, 1571-1577.	3.4	16
258	Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.8	64
259	Relationship between disease activity indices and their individual components and radiographic progression in RA: a systematic literature review. Rheumatology, 2015, 54, 994-1007.	1.9	51
260	Nonsteroidal Anti-inflammatory Drugs for Treatment of Acute Gout. JAMA - Journal of the American Medical Association, 2015, 313, 2276.	7.4	12
261	Accelerometer Quantification of Physical Activity and Activity Patterns in Patients with Ankylosing Spondylitis and Population Controls. Journal of Rheumatology, 2015, 42, 2369-2375.	2.0	25
262	Quality in rheumatoid arthritis care. Best Practice and Research in Clinical Rheumatology, 2015, 29, 664-679.	3.3	11
263	Evaluating patient reported outcomes in routine practice of patients with rheumatoid arthritis treated with biological disease modifying anti rheumatic drugs (b-DMARDs). SpringerPlus, 2015, 4, 462.	1.2	9
264	Spondyloarthritis features forecasting the presence of HLA-B27 or sacroiliitis on magnetic resonance imaging in patients with suspected axial spondyloarthritis: results from a cross-sectional study in the ESPeranza Cohort. Arthritis Research and Therapy, 2015, 17, 265.	3.5	6
265	Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts. RMD Open, 2015, 1, e000128.	3.8	17
266	Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS. Rheumatology, 2015, 54, 633-640.	1.9	57
267	Analysis of Integrated Radiographic Data From Two Long-Term, Open-Label Extension Studies of Adalimumab for the Treatment of Rheumatoid Arthritis. Arthritis Care and Research, 2015, 67, 180-186.	3.4	13
268	Reference intervals of spinal mobility measures in normal individuals: the mobility study. Annals of the Rheumatic Diseases, 2015, 74, 1218-1224.	0.9	45
269	Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2015, 386, 1137-1146.	13.7	722
270	Reply. Arthritis and Rheumatology, 2015, 67, 856-857.	5.6	0

#	ARTICLE	IF	CITATIONS
271	14-3-3 ¹ Autoantibodies: Diagnostic Use in Early Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2015, 42, 1587-1594.	2.0	28
272	Development of an ASAS-endorsed recommendation for the early referral of patients with a suspicion of axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1483-1487.	0.9	99
273	Clinical Tools to Assess and Monitor Spondyloarthritis. <i>Current Rheumatology Reports</i> , 2015, 17, 47.	4.7	63
274	Metric Properties of the SPARCC Score of the Sacroiliac Joints " Data from Baseline, 3-month, and 12-month Followup in the SPACE Cohort. <i>Journal of Rheumatology</i> , 2015, 42, 1186-1193.	2.0	23
275	Brief Report: Calculating the Ankylosing Spondylitis Disease Activity Score If the Conventional C-reactive Protein Level Is Below the Limit of Detection or If High-sensitivity C-reactive Protein Is Used: An Analysis in the DESIR Cohort. <i>Arthritis and Rheumatology</i> , 2015, 67, 408-413.	5.6	50
276	New analysis tools for observational studies. <i>Zeitschrift Fur Rheumatologie</i> , 2015, 74, 113-118.	1.0	1
277	Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor \pm inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study. <i>Arthritis Research and Therapy</i> , 2015, 17, 14.	3.5	49
278	Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 963-969.	0.9	36
279	Conventional DMARDs in axial spondyloarthritis: wishful"rather than rational"thinking!. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 951-953.	0.9	7
280	Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2015, 373, 1329-1339.	27.0	629
281	Report from the OMERACT Hand Osteoarthritis Working Group: Set of Core Domains and Preliminary Set of Instruments for Use in Clinical Trials and Observational Studies. <i>Journal of Rheumatology</i> , 2015, 42, 2190-2197.	2.0	62
282	Intra-articular etanercept treatment in inflammatory arthritis: A randomized double-blind placebo-controlled proof of mechanism clinical trial validating TNF as a potential therapeutic target for local treatment. <i>Joint Bone Spine</i> , 2015, 82, 338-344.	1.6	16
283	Quality indicators in rheumatoid arthritis: results from the METEOR database. <i>Rheumatology</i> , 2015, 54, 1630-1639.	1.9	23
284	Relationship between types of radiographic damage and disability in patients with rheumatoid arthritis in the EURIDISS cohort: a longitudinal study. <i>Rheumatology</i> , 2015, 54, 83-90.	1.9	28
285	Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 52-59.	0.9	174
286	Comparison of Tests for Lumbar Flexion and Hip Function in Patients With and Without Axial Spondyloarthritis. <i>Arthritis Care and Research</i> , 2015, 67, 538-545.	3.4	12
287	Predictors for health improvement in patients with fibromyalgia: a 2-year follow-up study. <i>Clinical Rheumatology</i> , 2015, 34, 133-141.	2.2	5
288	Defining an optimal referral strategy for patients with a suspicion of axial spondyloarthritis: what is really important? Response to: "Evaluating the ASAS recommendations for early referral of axial spondyloarthritis in patients with chronic low back pain; is one parameter present sufficient for primary care practice?" by van Hoeven et al. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1-1.	0.9	3

#	ARTICLE	IF	CITATIONS
289	85.â€fFinal 5-Year Safety and Efficacy Results of a Phase 3, Randomized, Placebo-Controlled Trial of Golimumab in Patients with Active Rheumatoid Arthritis Despite Previous Anti-Tumor Necrosis Factor Therapy. <i>Rheumatology</i> , 2014, 53, i87-i88.	1.9	2
290	How to Choose Core Outcome Measurement Sets for Clinical Trials: OMERACT 11 Approves Filter 2.0. <i>Journal of Rheumatology</i> , 2014, 41, 1025-1030.	2.0	78
291	Longterm Effect of Delaying Combination Therapy with Tumor Necrosis Factor Inhibitor in Patients with Aggressive Early Rheumatoid Arthritis: 10-year Efficacy and Safety of Adalimumab from the Randomized Controlled PREMIER Trial with Open-label Extension. <i>Journal of Rheumatology</i> , 2014, 41, 5-14.	2.0	50
292	Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1811-1818.	0.9	29
293	Neutral lateral fingertip-to-floor distance can be derived from height. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1748-1749.	0.9	2
294	Non-steroidal anti-inflammatory drugs for acute gout. <i>The Cochrane Library</i> , 2014, , CD010120.	2.8	40
295	Editorial: How Publication Bias May Harm Treatment Guidelines. <i>Arthritis and Rheumatology</i> , 2014, 66, 2661-2663.	5.6	5
296	Comment on: â€Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): a randomised, controlled clinical trialâ€™ by Qian-wen<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e62-e62.	0.9	13
297	How to deal with missing items in BASDAI and BASFI. <i>Rheumatology</i> , 2014, 53, 374-376.	1.9	5
298	Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example: TableÂ1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1755-1760.	0.9	11
299	Updating the OMERACT Filter: Core Areas as a Basis for Defining Core Outcome Sets. <i>Journal of Rheumatology</i> , 2014, 41, 994-999.	2.0	20
300	Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 745-753.	5.0	625
301	Proposal for a new nomenclature of disease-modifying antirheumatic drugs: TableÂ1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 3-5.	0.9	212
302	Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 516-528.	0.9	270
303	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 529-535.	0.9	456
304	Serum 14-3-3Î is a Novel Marker that Complements Current Serological Measurements to Enhance Detection of Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 2104-2113.	2.0	72
305	Effects of Cardiovascular Comorbidities on Work Participation in Rheumatic Diseases: A Prospective Cohort Study Among Working Individuals. <i>Arthritis Care and Research</i> , 2014, 66, 157-163.	3.4	7
306	Brief Report: Erosions and Sclerosis on Radiographs Precede the Subsequent Development of Syndesmophytes at the Same Site: A Twelveâ€Year Prospective Followup of Patients With Ankylosing Spondylitis. <i>Arthritis and Rheumatology</i> , 2014, 66, 2773-2779.	5.6	19

#	ARTICLE	IF	CITATIONS
307	Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2094-2100.	0.9	45
308	Aspects of validity of the self-administered comorbidity questionnaire in patients with ankylosing spondylitis. <i>Rheumatology</i> , 2014, 53, 1054-1064.	1.9	29
309	Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 510-515.	0.9	123
310	Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1455-1461.	0.9	263
311	How well are the ASAS/OMERACT Core Outcome Sets for Ankylosing Spondylitis implemented in randomized clinical trials? A systematic literature review. <i>Clinical Rheumatology</i> , 2014, 33, 1313-1322.	2.2	41
312	Assessment of global disease activity in RA patients monitored in the METEOR database: the patient's versus the rheumatologist's opinion. <i>Clinical Rheumatology</i> , 2014, 33, 461-466.	2.2	15
313	Intra articular injection with corticosteroids in patients with recent onset rheumatoid arthritis: subanalyses from the BeSt study. <i>Clinical Rheumatology</i> , 2014, 33, 263-267.	2.2	21
314	14-3-3 β is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage. <i>Arthritis Research and Therapy</i> , 2014, 16, R99.	3.5	61
315	Bone Marrow Edema on Magnetic Resonance Imaging (MRI) of the Sacroiliac Joints Is Associated with Development of Fatty Lesions on MRI over a 1-year Interval in Patients with Early Inflammatory Low Back Pain: A 2-year Followup Study. <i>Journal of Rheumatology</i> , 2014, 41, 1088-1094.	2.0	8
316	Comparison of characteristics of international and national databases for rheumatoid arthritis: a systematic literature review. <i>Scandinavian Journal of Rheumatology</i> , 2014, 43, 349-355.	1.1	2
317	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 492-509.	0.9	1,688
318	The Concept of Axial Spondyloarthritis: Joint Statement of the Spondyloarthritis Research and Treatment Network and the Assessment of SpondyloArthritis international Society in Response to the US Food and Drug Administration's Comments and Concerns. <i>Arthritis and Rheumatology</i> , 2014, 66, 2649-2656.	5.6	81
319	Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 6-16.	0.9	397
320	Scoring radiographic progression in ankylosing spondylitis: should we use the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) or the Radiographic Ankylosing Spondylitis Spinal Score (RASSS)?. <i>Arthritis Research and Therapy</i> , 2013, 15, R14.	3.5	48
321	Is it time to replace BASDAI with ASDAS?. <i>Nature Reviews Rheumatology</i> , 2013, 9, 388-390.	8.0	29
322	Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2013, 382, 1705-1713.	13.7	518
323	EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 804-814.	0.9	504
324	Editorial: Methotrexate saves lives: A pearl of observational research. <i>Arthritis and Rheumatism</i> , 2013, 65, 307-309.	6.7	10

#	ARTICLE	IF	CITATIONS
325	ASAS modification of the Berlin algorithm for diagnosing axial spondyloarthritis: results from the SPondyloArthritis Caught Early (SPACE)-cohort and from the Assessment of SpondyloArthritis international Society (ASAS)-cohort. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1646-1653.	0.9	127
326	Challenges in demonstrating the effectiveness of multidisciplinary treatment on quality of life, participation and health care utilisation in patients with fibromyalgia: a randomised controlled trial. <i>Clinical Rheumatology</i> , 2013, 32, 199-209.	2.2	35
327	Smoking and overweight determine the likelihood of developing rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1654-1658.	0.9	150
328	Application of the 2010 ACR/EULAR classification criteria in patients with very early inflammatory arthritis: analysis of sensitivity, specificity and predictive values in the SAVE study cohort. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1335-1341.	0.9	36
329	Ankylosing spondylitis patients with and without psoriasis do not differ in disease phenotype. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1104-1107.	0.9	18
330	Increase in Bone Density in Patients with Spondyloarthritis During Anti-Tumor Necrosis Factor Therapy: 6-year Followup Study. <i>Journal of Rheumatology</i> , 2013, 40, 1712-1718.	2.0	44
331	Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1156-1162.	0.9	56
332	Rate of adjudication of radiological progression in rheumatoid arthritis randomized controlled trials depending on preset limits of agreement: a pooled analysis from 15 randomized trials. <i>Rheumatology</i> , 2013, 52, 1404-1407.	1.9	2
333	EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 479-481.	0.9	114
334	From inhibition of radiographic progression to maintaining structural integrity: a methodological framework for radiographic progression in rheumatoid arthritis and psoriatic arthritis clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1113-1117.	0.9	24
335	SP0064â€¦Spondyloarthritis: What is new for primary care?. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 16.2-16.	0.9	0
336	Prevalence of Self-Reported Spondyloarthritis Features in a Cohort of Patients with Inflammatory Bowel Disease. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2013, 27, 199-205.	1.7	53
337	Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial. <i>Rheumatology</i> , 2012, 51, 1628-1638.	1.9	38
338	Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1671-1679.	0.9	53
339	How Do Gastrointestinal or Liver Comorbidities Influence the Choice of Pain Treatment in Inflammatory Arthritis? A Cochrane Systematic Review. <i>Journal of rheumatology Supplement</i> , The, 2012, 90, 74-80.	2.2	10
340	Development of new syndesmophytes and bridges in ankylosing spondylitis and their predictors: a longitudinal study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 518-523.	0.9	130
341	MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 2002-2005.	0.9	87
342	MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 369-373.	0.9	126

#	ARTICLE	IF	CITATIONS
343	Are syndesmophytes most prevalent in the lumbar or in the cervical spine in patients with ankylosing spondylitis and do they develop in a specific direction?. Rheumatology, 2012, 51, 1432-1439.	1.9	14
344	EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis. Annals of the Rheumatic Diseases, 2012, 71, 13-19.	0.9	148
345	Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing) Tj ETQq1 1 0.784314 rgBT /Overlock Library, 2012, 1, CD008951.	2.8	36
346	Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases, 2012, 71, 1623-1629.	0.9	223
347	Comorbidities in Patients with Spondyloarthritis. Rheumatic Disease Clinics of North America, 2012, 38, 523-538.	1.9	33
348	Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI study group. Annals of the Rheumatic Diseases, 2012, 71, 1278-1288.	0.9	218
349	OMERACT 10 Sharp Symposium: Important Findings in Examination of Imaging Methods for Measurement of Joint Damage in Rheumatoid Arthritis. Journal of Rheumatology, 2011, 38, 2009-2013.	2.0	4
350	Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Annals of the Rheumatic Diseases, 2011, 70, 47-53.	0.9	589
351	American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials. Annals of the Rheumatic Diseases, 2011, 70, 404-413.	0.9	657
352	2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Annals of the Rheumatic Diseases, 2011, 70, 905-908.	0.9	365
353	Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing) Tj ETQq1 1 0.784314 rgBT /Overlock Library, 2012, 1, CD008951.	2.8	48
354	Endorsement of Definitions of Disease Activity States and Improvement Scores for the Ankylosing Spondylitis Disease Activity Score: Results from OMERACT 10. Journal of Rheumatology, 2011, 38, 1502-1506.	2.0	52
355	American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis and Rheumatism, 2011, 63, 573-586.	6.7	864
356	On publication policy, combination therapy, and the European League Against Rheumatism recommendations for the management of rheumatoid arthritis: Comment on the article by Graudal et al. Arthritis and Rheumatism, 2011, 63, 3182-3185.	6.7	1
357	Dramatic Repair of Joint Damage in Psoriatic Arthritis. Journal of Rheumatology, 2011, 38, 969-970.	2.0	2
358	Diagnostic and Prognostic Value of Synovial Biopsy in Adult Undifferentiated Peripheral Inflammatory Arthritis: A Systematic Review. Journal of rheumatology Supplement, The, 2011, 87, 45-47.	2.2	13
359	Diagnostic and Predictive Value of Acute-phase Reactants in Adult Undifferentiated Peripheral Inflammatory Arthritis: A Systematic Review. Journal of rheumatology Supplement, The, 2011, 87, 15-19.	2.2	7
360	Algorithm for Identification of Undifferentiated Peripheral Inflammatory Arthritis: A Multinational Collaboration Through the 3e Initiative. Journal of rheumatology Supplement, The, 2011, 87, 54-58.	2.2	11

#	ARTICLE	IF	CITATIONS
361	Joint space narrowing, cartilage and physical function: are we deceived by measurements and distributions?. Annals of the Rheumatic Diseases, 2011, 70, 717-718.	0.9	16
362	Damage and Progression on Radiographs in Individual Joints: Data from Pivotal Randomized Controlled Trials. Journal of Rheumatology, 2011, 38, 2018-2022.	2.0	20
363	OMERACT Magnetic Resonance Imaging Initiative on Structural and Inflammatory Lesions in Ankylosing Spondylitis â€” Report of a Special Interest Group at OMERACT 10 on Sacroiliac Joint and Spine Lesions. Journal of Rheumatology, 2011, 38, 2051-2054.	2.0	19
364	A stratified model for health outcomes in ankylosing spondylitis. Annals of the Rheumatic Diseases, 2011, 70, 1758-1764.	0.9	65
365	Biologicals and switch in rheumatoid arthritis throughout time - are we being more aggressive?. Acta ReumatolÃ³gica Portuguesa, 2011, 36, 234-42.	0.2	0
366	Disease Activity, Physical Function, and Radiographic Progression After Longterm Therapy with Adalimumab Plus Methotrexate: 5-Year Results of PREMIER. Journal of Rheumatology, 2010, 37, 2237-2246.	2.0	80
367	Characterisation and potential diagnostic value of circulating matrix Gla protein (MGP) species. Thrombosis and Haemostasis, 2010, 104, 811-822.	3.4	207
368	Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases, 2010, 69, 1465-1470.	0.9	244
369	The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. Annals of the Rheumatic Diseases, 2010, 69, 495-502.	0.9	136
370	A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial. Annals of the Rheumatic Diseases, 2010, 69, 1430-1435.	0.9	93
371	Repair of erosions occurs almost exclusively in damaged joints without swelling. Annals of the Rheumatic Diseases, 2010, 69, 851-855.	0.9	60
372	Magnetic Resonance Imaging in the Diagnosis of Ankylosing Spondylitis: Be Aware of Gold Standards and Circularity. Journal of Rheumatology, 2010, 37, 477-478.	2.0	10
373	Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost. Annals of the Rheumatic Diseases, 2010, 69, 1123-1128.	0.9	110
374	Justification for including MRI as a tool in the diagnosis of axial SpA. Nature Reviews Rheumatology, 2010, 6, 670-672.	8.0	19
375	Intranasal administration of recombinant human cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: a phase II, multicentre, double-blind, randomised, placebo-controlled, parallel-group, dose-finding trial. Annals of the Rheumatic Diseases, 2010, 69, 1655-1659.	0.9	10
376	Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2010, 69, 1623-1628.	0.9	95
377	Adenosine 5'-triphosphate infusions reduced disease activity and inflammation in a patient with active rheumatoid arthritis. Rheumatology, 2010, 49, 2223-2225.	1.9	8
378	RAPID and FAST4WARD trials: certolizumab pegol for rheumatoid arthritis. Expert Review of Clinical Immunology, 2010, 6, 713-720.	3.0	11

#	ARTICLE	IF	CITATIONS
379	A Randomized Trial of Tai Chi for Fibromyalgia. <i>New England Journal of Medicine</i> , 2010, 363, 2265-2267.	27.0	7
380	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 964-975.	0.9	1,429
381	EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1596-1602.	0.9	87
382	Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 995-1003.	0.9	122
383	Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1004-1009.	0.9	179
384	Efficacy assessed in follow-ups of clinical trials: methodological conundrum. <i>Arthritis Research and Therapy</i> , 2010, 12, 132.	3.5	3
385	Tools for monitoring spondyloarthritis in clinical practice. <i>Nature Reviews Rheumatology</i> , 2009, 5, 608-615.	8.0	5
386	Multiple Computer-based Methods of Measuring Joint Space Width Can Discriminate Between Treatment Arms in the COBRA Trial – Update of an Ongoing OMERACT Project. <i>Journal of Rheumatology</i> , 2009, 36, 1825-1828.	2.0	13
387	American College of Rheumatology recommendations for the treatment of RA: an issue of choices. <i>Nature Clinical Practice Rheumatology</i> , 2009, 5, 8-9.	3.2	3
388	Proposal for Levels of Evidence Schema for Validation of a Soluble Biomarker Reflecting Damage Endpoints in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis, and Recommendations for Study Design. <i>Journal of Rheumatology</i> , 2009, 36, 1792-1799.	2.0	38
389	Reappraisal of OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage Endpoints in Rheumatoid Arthritis, Psoriatic Arthritis, and Spondyloarthritis: The OMERACT 9 v2 Criteria. <i>Journal of Rheumatology</i> , 2009, 36, 1785-1791.	2.0	40
390	Testing of the OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage in Rheumatoid Arthritis: A Systematic Literature Search on 5 Candidate Biomarkers. <i>Journal of Rheumatology</i> , 2009, 36, 1769-1784.	2.0	21
391	The feasibility and efficacy of a multidisciplinary intervention with aftercare meetings for fibromyalgia. <i>Clinical Rheumatology</i> , 2009, 28, 923-929.	2.2	21
392	Cartilage and Bone Biomarkers in Rheumatoid Arthritis: Prediction of 10-year Radiographic Progression. <i>Journal of Rheumatology</i> , 2009, 36, 266-272.	2.0	59
393	Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. <i>Arthritis Research and Therapy</i> , 2009, 11, R127.	3.5	357
394	Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. <i>Lancet</i> , 2009, 374, 210-221.	13.7	497
395	Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2008, 58, 3063-3070.	6.7	461
396	Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. <i>Arthritis and Rheumatism</i> , 2008, 58, 3319-3329.	6.7	539

#	ARTICLE	IF	CITATIONS
397	Searching for potential biomarkers that can be used as biomarkers for diagnosing ankylosing spondylitis. <i>Biomarkers in Medicine</i> , 2008, 2, 23-30.	1.4	0
398	Primer: challenges in randomized and observational studies. <i>Nature Clinical Practice Rheumatology</i> , 2007, 3, 661-666.	3.2	21
399	How do the EQ-5D, SF-6D and the well-being rating scale compare in patients with ankylosing spondylitis?. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 771-777.	0.9	36
400	Associations between the PTPN22 1858C->T polymorphism and radiographic joint destruction in patients with rheumatoid arthritis: results from a 10-year longitudinal study. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1604-1609.	0.9	37
401	Tumour necrosis factor blockers and structural remodelling in ankylosing spondylitis: what is reality and what is fiction?. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 709-711.	0.9	53
402	Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1093-1097.	0.9	126
403	Expert agreement confirms that negative changes in hand and foot radiographs are a surrogate for repair in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2007, 9, R62.	3.5	24
404	Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2007, 56, 1846-1853.	6.7	151
405	Dickkopf-1 is a master regulator of joint remodeling. <i>Nature Medicine</i> , 2007, 13, 156-163.	30.7	1,161
406	Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. <i>Journal of Rheumatology</i> , 2007, 34, 607-15.	2.0	78
407	Scoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: a multireader experiment. <i>Journal of Rheumatology</i> , 2007, 34, 862-70.	2.0	97
408	Is there a preferred method for scoring activity of the spine by magnetic resonance imaging in ankylosing spondylitis?. <i>Journal of Rheumatology</i> , 2007, 34, 871-3.	2.0	31
409	International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. <i>Journal of Rheumatology</i> , 2007, 34, 1740-5.	2.0	74
410	The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28. <i>Arthritis Research and Therapy</i> , 2006, 8, 107.	3.5	9
411	Magnetic resonance imaging changes of sacroiliac joints in patients with recent-onset inflammatory back pain: inter-reader reliability and prevalence of abnormalities. <i>Arthritis Research and Therapy</i> , 2006, 8, R11.	3.5	51
412	Imaging in ankylosing spondylitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2006, 20, 507-519.	3.3	31
413	Association of early radiographic damage with impaired physical function in rheumatoid arthritis: A ten-year, longitudinal observational study in 238 patients. <i>Arthritis and Rheumatism</i> , 2006, 54, 68-75.	6.7	137
414	Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: Results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. <i>Arthritis and Rheumatism</i> , 2006, 54, 1646-1652.	6.7	220

#	ARTICLE	IF	CITATIONS
415	Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: Results from the trial of etanercept and methotrexate with radiographic and patient outcomes. <i>Arthritis and Rheumatism</i> , 2006, 54, 3119-3125.	6.7	159
416	Imaging in spondylitis. <i>Current Opinion in Rheumatology</i> , 2005, 17, 413-417.	4.3	20
417	Presentation and analysis of data on radiographic outcome in clinical trials: Experience from the TEMPO study. <i>Arthritis and Rheumatism</i> , 2005, 52, 49-60.	6.7	96
418	Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: A randomized clinical trial. <i>Arthritis and Rheumatism</i> , 2005, 52, 1756-1765.	6.7	623
419	How should treatment effect on spinal radiographic progression in patients with ankylosing spondylitis be measured?. <i>Arthritis and Rheumatism</i> , 2005, 52, 1979-1985.	6.7	41
420	Early aggressive therapy in rheumatoid arthritis: a 'window of opportunity'?. <i>Nature Clinical Practice Rheumatology</i> , 2005, 1, 2-3.	3.2	16
421	Application of the OMERACT filter to scoring methods for magnetic resonance imaging of the sacroiliac joints and the spine. Recommendations for a research agenda at OMERACT 7. <i>Journal of Rheumatology</i> , 2005, 32, 2042-7.	2.0	37
422	Scoring sacroiliac joints by magnetic resonance imaging. A multiple-reader reliability experiment. <i>Journal of Rheumatology</i> , 2005, 32, 2050-5.	2.0	60
423	Magnetic resonance imaging of inflammatory lesions in the spine in ankylosing spondylitis clinical trials: is paramagnetic contrast medium necessary?. <i>Journal of Rheumatology</i> , 2005, 32, 2056-60.	2.0	56
424	Responsiveness and discriminative capacity of the assessments in ankylosing spondylitis disease-controlling antirheumatic therapy core set and other outcome measures in a trial of etanercept in ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2004, 51, 1-8.	6.7	40
425	Radiographic progression depicted by probability plots: Presenting data with optimal use of individual values. <i>Arthritis and Rheumatism</i> , 2004, 50, 699-706.	6.7	69
426	Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2004, 50, 1390-1399.	6.7	87
427	The influence of peripheral arthritis on disease activity in ankylosing spondylitis patients as measured with the Bath Ankylosing Spondylitis Disease Activity Index. <i>Arthritis and Rheumatism</i> , 2004, 51, 154-159.	6.7	63
428	The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: A longitudinal analysis. <i>Arthritis and Rheumatism</i> , 2004, 50, 2082-2093.	6.7	227
429	What is the most appropriate radiologic scoring method for ankylosing spondylitis?. <i>Arthritis and Rheumatism</i> , 2004, 50, 2622-2632.	6.7	335
430	Measurement of spinal mobility in ankylosing spondylitis: comparison of occiput-to-wall and tragus-to-wall distance. <i>Journal of Rheumatology</i> , 2004, 31, 1779-84.	2.0	26
431	Principles of assessment from a clinical perspective. <i>Best Practice and Research in Clinical Rheumatology</i> , 2003, 17, 365-379.	3.3	10
432	The benefits of early treatment in rheumatoid arthritis: Confounding by indication, and the issue of timing. <i>Arthritis and Rheumatism</i> , 2003, 48, 1-5.	6.7	78

#	ARTICLE	IF	CITATIONS
433	Does cyclosporin A cause cancer?. Nature Medicine, 1999, 5, 714-714.	30.7	18